CDS + HHFNC Weaning for Bronchiolitis
(REST EEC Trial)
Trial Summary
What is the purpose of this trial?
This project aims to answer the essential questions about the management of acute, pediatric respiratory illness, accelerate recovery from these all-too-common diseases, curb unnecessary costs of care, and demonstrate UPMC Children's Hospital of Pittsburgh's capabilities as the premier, world-class leader in the arena of pediatric learning healthcare systems. REST EEC will focus on the question of whether clinical decision support (CDS) facilitates the standardization of the initiation and weaning of heated high flow nasal cannula (HHFNC) for bronchiolitis.REST EEC will focus on whether the application of CDS improves adherence to a standardized guideline and leads to improved patient-centered outcomes.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Clinical Decision Support (CDS) for bronchiolitis?
Clinical Decision Support (CDS) systems have been shown to improve decision-making in various medical conditions, such as reducing unnecessary antibiotic prescriptions for respiratory infections and improving care efficiency in pulmonary embolism cases. This suggests that CDS could potentially enhance treatment strategies for bronchiolitis as well.12345
Is the CDS system generally safe for use in humans?
The research indicates that Clinical Decision Support (CDS) systems are designed to improve patient safety by minimizing medication errors through alerts about drug interactions and allergies. However, there is a high rate of alert overrides by users, suggesting that the system's alerts may not always be specific or useful, which could impact safety.678910
How is the CDS + HHFNC Weaning treatment for bronchiolitis different from other treatments?
The CDS + HHFNC Weaning treatment for bronchiolitis is unique because it involves a structured approach to gradually reduce the use of high-flow nasal cannula (HFNC) therapy, which is a method of providing oxygen through a tube in the nose. This approach aims to optimize the duration and effectiveness of HFNC therapy, which is not standardized in current treatments.1112131415
Research Team
Christopher Horvat, MD
Principal Investigator
UPMC Children's Hospital of Pittsburgh
Eligibility Criteria
This trial is for children under 2 years old with bronchiolitis and a work of breathing (WOB) score greater than 2. It's not suitable for kids with congenital heart disease affecting their breathing, those who have weakened immune systems, or chronic lung conditions.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive heated high flow nasal cannula (HHFNC) with or without clinical decision support (CDS) for bronchiolitis
Follow-up
Participants are monitored for safety and effectiveness after treatment, including PICU and hospital length of stay, mortality, and respiratory support free days
Treatment Details
Interventions
- Clinical Decision Support (CDS)
- HHFNC Weaning
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Pittsburgh
Lead Sponsor
Christopher Horvat
Lead Sponsor
Beckwith Foundation
Collaborator